Xbrane Biopharma AB (publ) (STO:XBRANE)

Market Cap	196.99M -56.3%
Revenue (ttm)	83.30M -61.3%
Net Income	-75.00M
EPS	-3.95
Shares Out	20.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,563
Open	9.72
Previous Close	9.72
Day's Range	9.44 - 9.76
52-Week Range	5.42 - 38.10
Beta	0.85
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 17, 2026

About Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 29
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XBRANE

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 13, 2026

Data Sources Report a data error